Novo Nordisk’s Victoza helps patients achieve blood-sugar control when switching from exenatide or sitagliptin
SAN DIEGO — Novo Nordisk unveiled data from two extension studies at the 71st annual Scientific Sessions of the American Diabetes Association in San Diego that show its diabetes drug, when combined with other medications, may help patients achieve blood-sugar control.
The drug maker found that combining Victoza (liraglutide [rDNA origin] injection) with metformin and/or sulfonylurea helped patients achieve blood-sugar control.
Additionally, Novo Nordisk also presented data that showed that the addition of Levemir (insulin detemir [rDNA origin] injection) to Victoza and metformin helped patients reach and maintain blood sugar targets. The results also showed a low frequency of hypoglycemia and maintained weight loss among patients.
Both switch trials were extensions of randomized, open-label studies that compared the efficacy and safety of Victoza in 1.2-mg and/or 1.8-mg strengths, taken once daily, with twice-daily exenatide (10 μg) or sitagliptin (100 mg), all in combination with metformin and/or sulfonylurea.
“The results … are encouraging. Not only did Victoza treatment alone help more than 60% of patients achieve the ADA target for blood-sugar control, but also the addition of Levemir helped many of the remaining patients achieve the ADA target without the increases in hypoglycemia and body weight normally associated with insulin therapy,” Novo Nordisk EVP and chief science officer Mads Krogsgaard Thomsen said.
Garamycin ophthalmic solution enters market
NEW YORK — Fera Pharmaceuticals has launched an ocular bacterial infections treatment.
The company announced the launch of Garamycin (gentamicin sulfate) ophthalmic solution USP, designed to treat such infections as conjunctivitis, keratitis and blepharitis.
Last year, Fera broadened its Garamycin product offerings with the launch of preservative-free Garamycin ophthalmic ointment.
Study: Insulin lispro premixed insulin analogs may be more cost-effective Type 2 diabetes treatment
SAN DIEGO — An insulin product made by Eli Lilly appears likely to be more cost-effective than long-acting insulin analog, according to a study presented Friday at the American Diabetes Association’s 71st Scientific Sessions in San Diego.
The company conducted a study comparing the cost-effectiveness of LAIA, insulin lispro mix 75/25 and insulin lispro mix 50/50 in patients with Type 2 diabetes. Lilly sells insulin lispro under the brand name Humalog.
Analysis of the study found that for patients who do not experience frequent hypoglycemia, insulin lispro premixed insulin analogs are likely to be more cost-effective than LAIA in the long-term treatment of the disease.